How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

14,624 results for

Systemic Lupus Erythematosus

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Systemic lupus erythematosus

Systemic lupus erythematosus Evidence Maps - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Proof of concept – note only works for conditions, do not add interventions into the search box! This is a beta ‘proof of concept’ of a fully automated evidence mapping system. It is experimental and therefore the results should be dealt with appropriate scepticism. To understand more of what the system does . Please send feedback to (we will only get better by constructive feedback). For a list

2018 Trip Evidence Maps

2. Belimumab (Benlysta ) - systemic lupus erythematosus

Belimumab (Benlysta ) - systemic lupus erythematosus belimumab | CADTH.ca Find the information you need belimumab belimumab Last Updated: October 1, 2019 Result type: Reports Project Number: SR0616-000 Product Line: Generic Name: Belimumab Brand Name: Benlysta Manufacturer: GlaxoSmithKline Inc. Indications: systemic lupus erythematosus Manufacturer Requested Reimbursement Criteria 1 : For the treatment of SLE patients who meet the following eligibility criteria: Adult patients age 18 years

2019 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

3. Systemic lupus erythematosus

Systemic lupus erythematosus Systemic lupus erythematosus - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Systemic lupus erythematosus Last reviewed: February 2019 Last updated: August 2018 Summary Generalised disorder that can affect any system. Symptoms and signs may accumulate over time. The diagnosis is made using criteria recommended by the American College of Rheumatology. Treatments for mild to moderate (...) serositis or arthritis include hydroxychloroquine, non-steroidal anti-inflammatory drugs, or corticosteroids. Treatments for more severe disease may include cyclophosphamide, mycophenolate, or tacrolimus plus corticosteroids. Definition Systemic lupus erythematosus (SLE) is a chronic multi-system disorder that most commonly affects women during their reproductive years. It is characterised by the presence of antinuclear antibodies. In addition to constitutional symptoms, it most frequently involves

2018 BMJ Best Practice

4. Canadian Rheumatology Association recommendations for the assessment and monitoring of systemic lupus erythematosus

Canadian Rheumatology Association recommendations for the assessment and monitoring of systemic lupus erythematosus The Journal of Rheumatology and Monitoring of Systemic Lupus Erythematosus Canadian Rheumatology Association Recommendations for the Assessment Touma, Evelyne Vinet and Nancy Santesso Reynolds, Earl Silverman, Konstantinos Tselios, Manon Suitner, Murray Urowitz, Zahi Jordi Pardo Pardi, Christine Peschken, Christian Pineau, Janet Pope, Tamara Rader, Jen Legault, Deborah Levy, Lily (...) 26, 2019 - Published by www.jrheum.org Downloaded from 1 Keeling, et al: Canadian SLE recommendations assessment Personal non-commercial use only. The Journal of Rheumatology Copyright © 2018. All rights reserved. Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus Stephanie O. Keeling, Zainab Alabdurubalnabi, Antonio Avina-Zubieta, Susan Barr, Louise Bergeron, Sasha Bernatsky, Josiane Bourre-Tessier, Ann Clarke, Alexandra Baril

2018 CPG Infobase

5. Belimumab Treatment for Adults with Systemic Lupus Erythematosus: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Belimumab Treatment for Adults with Systemic Lupus Erythematosus: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Belimumab Treatment for Adults with Systemic Lupus Erythematosus: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Belimumab Treatment for Adults with Systemic Lupus Erythematosus: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Belimumab Treatment for Adults with Systemic (...) Lupus Erythematosus: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Last updated: May 23, 2018 Project Number: RC0989-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of belimumab for the treatment of adults with systemic lupus erythematosus? What is the cost-effectiveness of belimumab for the treatment of adults with systemic lupus erythematosus? What are the evidence-based

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

8. Plaquenil (hydroxychloroquine sulfate) - Long-acting symptomatic treatment of rheumatoid arthritis, Discoid lupus erythematosus, Subacute lupus erythematosus, systemic lupus erythematosus, Prevention of polymorphous light eruption

Plaquenil (hydroxychloroquine sulfate) - Long-acting symptomatic treatment of rheumatoid arthritis, Discoid lupus erythematosus, Subacute lupus erythematosus, systemic lupus erythematosus, Prevention of polymorphous light eruption HAS - Medical, Economic and Public Health Assessment Division 1/11 The legally binding text is the original French version T TR RA AN NS SP PA AR RE EN NC CY Y C CO OM MM MI IT TT TE EE E Opinion 23 July 2014 PLAQUENIL 200 mg, film-coated tablet B/30 (CIP: 34009 364 (...) 414 6 0) Applicant: SANOFI-AVENTIS France INN hydroxychloroquine sulfate ATC code (2014) P01BA02 (synthetic antimalarials) Reason for the review Renewal of inclusion List concerned National Health Insurance (French Social Security Code L.162-17) Indications concerned “Long-acting symptomatic treatment of rheumatoid arthritis, Discoid lupus erythematosus, Subacute lupus erythematosus, Adjuvant or preventive treatment of relapses of systemic lupus erythematosus, Prevention of polymorphous light

2015 Haute Autorite de sante

9. Cutaneous lupus erythematosus patients with a negative antinuclear antibody meeting the American College of Rheumatology and/or Systemic Lupus International Collaborating Clinics criteria for systemic lupus erythematosus. Full Text available with Trip Pro

Cutaneous lupus erythematosus patients with a negative antinuclear antibody meeting the American College of Rheumatology and/or Systemic Lupus International Collaborating Clinics criteria for systemic lupus erythematosus. Systemic lupus erythematosus (SLE) is a disorder that is heterogeneous and can be difficult to diagnose. One hallmark of the disease is the presence of antinuclear antibodies (ANA), a feature that has been incorporated into multiple classification criteria over the years (...) . In this study, we use a database of cutaneous lupus erythematosus (CLE) patients to determine how many have a negative ANA and meet criteria for SLE using the ACR and/or SLICC criteria.We used a database of 301 biopsy-proven CLE patients that contained information including ANA status and the presence of features of SLE. The database was searched for patients who had a negative ANA and whether or not they met SLE criteria using the ACR and/or SLICC criteria.Of the 301 patients with biopsy-proven CLE

2019 Arthritis care & research

10. Comparison of Sensitivities of American College of Rheumatology and Systemic Lupus International Collaborating Clinics Classification Criteria in Childhood-onset Systemic Lupus Erythematosus (Abstract)

Comparison of Sensitivities of American College of Rheumatology and Systemic Lupus International Collaborating Clinics Classification Criteria in Childhood-onset Systemic Lupus Erythematosus Currently there are 2 different classification criteria for systemic lupus erythematosus (SLE): American College of Rheumatology (ACR) and Systemic Lupus International Collaborating Clinics (SLICC). The aim of this study was to compare the sensitivities of ACR and SLICC criteria in childhood-onset SLE (cSLE (...) ) using a large, multiethnic cohort.We conducted a retrospective study of 722 patients diagnosed with cSLE at The Hospital for Sick Children (SickKids). Prospectively collected data from SickKids' Lupus Database were reviewed/validated against medical records prior to ACR and SLICC scoring based on cumulative symptoms up to the last visit. Sensitivities were compared using McNemar's test. Descriptive statistics were used to identify SLE features unique to each set of criteria and autoantibodies

2019 EvidenceUpdates

11. Belimumab (Benlysta) for the treatment of adult patients with auto-antibody-positive systemic lupus erythematosus (SLE)

Belimumab (Benlysta) for the treatment of adult patients with auto-antibody-positive systemic lupus erythematosus (SLE) Belimumab (Benlysta®) for the treatment of adult patients with auto-antibody-positive systemic lupus erythematosus (SLE) | Report | National Health Care Institute You are here: Belimumab (Benlysta®) for the treatment of adult patients with auto-antibody-positive systemic lupus erythematosus (SLE) Search within English part of National Health Care Institute Search Belimumab (...) (Benlysta®) for the treatment of adult patients with auto-antibody-positive systemic lupus erythematosus (SLE) Zorginstituut Nederland has carried out an assessment of the medicinal product subcutaneous belimumab (Benlysta®) and a re-assessment of intravenous belimumab, the latter of which is subject to Conditional Inclusion in the insured standard package. Outcome of assessment of belimumab The Zorginstituut establishes that the addition of both the subcutaneous and the intravenous delivery

2018 National Health Care Institute (Zorginstituut Nederland)

12. Predisposing factors to nonfatal cardiovascular events in women with systemic lupus erythematosus. An observational, cross-sectional, multicenter study in Spain from the risk/systemic lupus erythematosus thematic network. Full Text available with Trip Pro

Predisposing factors to nonfatal cardiovascular events in women with systemic lupus erythematosus. An observational, cross-sectional, multicenter study in Spain from the risk/systemic lupus erythematosus thematic network. Very few studies have been published on cardiovascular morbidity in Spanish patients diagnosed with systemic lupus erythematosus (SLE). Moreover, knowledge of the predictive factors for the occurrence of nonfatal events in this group of patients is scarce.This (...) ] odds ratio [OR] = 1.024-1.27, P = .017) and the systemic lupus international collaborating clinics (SLICC) chronicity index score (95% CI OR = 1.479-2.400, P = .000) resulted in an increase in the OR of these patients presenting a CVE. Regarding the classic risk factors, only the interaction between hypertension (HT) and treatment with antihypertensive drugs influenced the presence of CVEs (95% CI OR = 2.165-10.377, P = .000). The presence of a family history of early cardiovascular disease

2019 Medicine

13. A double-blind, randomized, placebo-controlled, phase II trial of baricitinib for systemic lupus erythematosus: how to optimize lupus trials to examine effects on cutaneous lupus erythematosus. Full Text available with Trip Pro

A double-blind, randomized, placebo-controlled, phase II trial of baricitinib for systemic lupus erythematosus: how to optimize lupus trials to examine effects on cutaneous lupus erythematosus. 31025748 2019 11 20 1365-2133 180 5 2019 May The British journal of dermatology Br. J. Dermatol. A double-blind, randomized, placebo-controlled, phase II trial of baricitinib for systemic lupus erythematosus: how to optimize lupus trials to examine effects on cutaneous lupus erythematosus. 964-965

2019 The British journal of dermatology Controlled trial quality: predicted high

14. Time to progression from discoid lupus erythematosus to systemic lupus erythematosus: a retrospective cohort study. (Abstract)

Time to progression from discoid lupus erythematosus to systemic lupus erythematosus: a retrospective cohort study. Determining the risk of progression to systemic lupus erythematosus (SLE) among patients diagnosed with discoid lupus erythematosus (DLE), and the time frame of this risk, are important clinical questions. Past reports have demonstrated a wide time frame of progression from DLE to SLE, with mean time to progression of approximately 8 years. Using data obtained from an academic (...) lupus centre, we identified 32 patients who progressed from DLE to SLE. In our cohort, we found that the median time to progression from DLE to SLE was 453 days, much sooner than previously reported. We believe this information can help inform clinicians on monitoring visit intervals and how best to counsel patients on SLE progression.© 2019 British Association of Dermatologists.

2019 Clinical & Experimental Dermatology

15. IFN-alpha kinoid in systemic lupus erythematosus: results from a phase IIb, randomised, placebo-controlled study

IFN-alpha kinoid in systemic lupus erythematosus: results from a phase IIb, randomised, placebo-controlled study IFN-α Kinoid in Systemic Lupus Erythematosus: Results From a Phase IIb, Randomised, Placebo-Controlled Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features are temporarily unavailable. National (...) collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Ann Rheum Dis Actions 2019 Dec 23 [Online ahead of print] IFN-α Kinoid in Systemic Lupus Erythematosus: Results From a Phase IIb, Randomised, Placebo-Controlled Study , , , , , , , , , , , Affiliations Expand Affiliations 1 Pôle de Pathologies Rhumatismales Inflammatoires et Systémiques, Institut de Recherche Expérimentale

2020 EvidenceUpdates

16. Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach

Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach Neuropsychiatric Events in Systemic Lupus Erythematosus: A Longitudinal Analysis of Outcomes in an International Inception Cohort Using a Multistate Model Approach - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go (...) your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Ann Rheum Dis Actions , 79 (3), 356-362 Mar 2020 Neuropsychiatric Events in Systemic Lupus Erythematosus: A Longitudinal Analysis of Outcomes in an International Inception Cohort Using a Multistate Model Approach

2020 EvidenceUpdates

17. Systemic Lupus Erythematosus. (Abstract)

Systemic Lupus Erythematosus. Systemic lupus erythematosus (lupus) is characterized by aberrant activity of the immune system, leading to variable clinical symptoms. Lupus is more prevalent in African American women and women in other ethnic minority groups. Diagnosing, treating, and identifying novel therapies for lupus is challenging because of its genetic and phenotypic heterogeneity. Lupus nephritis is the most common target-organ manifestation and requires individualized care to minimize (...) toxicity. A multidisciplinary approach to caring for pregnant patients with lupus is essential to optimize outcomes.

2020 Annals of Internal Medicine

18. Trial of Anifrolumab in Active Systemic Lupus Erythematosus. (Abstract)

Trial of Anifrolumab in Active Systemic Lupus Erythematosus. Anifrolumab, a human monoclonal antibody to type I interferon receptor subunit 1 investigated for the treatment of systemic lupus erythematosus (SLE), did not have a significant effect on the primary end point in a previous phase 3 trial. The current phase 3 trial used a secondary end point from that trial as the primary end point.We randomly assigned patients in a 1:1 ratio to receive intravenous anifrolumab (300 mg) or placebo every (...) 4 weeks for 48 weeks. The primary end point of this trial was a response at week 52 defined with the use of the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA). A BICLA response requires reduction in any moderate-to-severe baseline disease activity and no worsening in any of nine organ systems in the BILAG index, no worsening on the Systemic Lupus Erythematosus Disease Activity Index, no increase of 0.3 points or more in the score on the Physician Global

2020 NEJM

19. Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase II Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Patients With Active Systemic Lupus Erythematosus

Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase II Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Patients With Active Systemic Lupus Erythematosus Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase II Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Patients With Active Systemic Lupus Erythematosus - PubMed This site needs JavaScript to work properly (...) Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Patients With Active Systemic Lupus Erythematosus , , , , , , , , , Affiliations Expand Affiliations 1 University of Amsterdam, Amsterdam, The Netherlands. 2 University of California, Los Angeles. 3 Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts. 4 AMPEL BioSolutions, LLC, Charlottesville, Virginia. 5 Janssen Research & Development, LLC, Spring House, Pennsylvania. PMID

2020 EvidenceUpdates

20. Comment on: Pediatric systemic lupus erythematosus: Retrospective analysis of clinico-laboratory parameters and their association with systemic lupus erythematosus disease activity index score Full Text available with Trip Pro

Comment on: Pediatric systemic lupus erythematosus: Retrospective analysis of clinico-laboratory parameters and their association with systemic lupus erythematosus disease activity index score [No Abstract Available].

2018 Saudi medical journal

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>